In GC, Axl overexpression has been linked to resistance against trastuzumab in HER2-positive tumors, as well as to acquired resistance to tyrosine kinase inhibitors (TKIs) targeting MET or FGFR2 [35]. Here, FGFR2 is linked to gastric cancer.